Ocuflox (Ofloxacin)

Generic Name

Ofloxacin

Brand Names

Ocuflox, Ofloxacin Ophth, Olfoxacin

FDA approval date: August 01, 1993

Classification: Quinolone Antimicrobial

Form: Tablet, Solution

What is Ocuflox (Ofloxacin)?

OCUFLOX ® ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: *Efficacy for this organism was studied in fewer than 10 infections CONJUNCTIVITIS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens* Streptococcus pneumoniae Anaerobic species: Propionibacterium acnes.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

BALANCE+: A Platform Trial for Gram Negative Bloodstream Infections

Enrollment Status: Recruiting

Publish Date: September 04, 2026

Intervention Type: Other

Study Phase: Not Applicable

Summary: BALANCE+ is a perpetual multiple domain randomized controlled platform trial to evaluate various treatment strategies for Gram-negative bloodstream infections (GN BSIs). Each domain addresses critical questions in the management of GN BSIs, aiming to refine treatment strategies, enhance patient outcomes, and reduce antimicrobial resistance. The initial vanguard pilot RCT (NCT05893147) started on 2...

Population Pharmacokinetic Model of Rifampicin in Staphylococcal Osteoarticular Infections

Enrollment Status: Recruiting

Publish Date: August 26, 2026

Intervention Type: Drug

Study Phase: Not Applicable

Objectives: The primary objective of this study is to develop a population pharmacokinetic model of oral rifampicin in patients undergoing medico-surgical treatment for staphylococcal osteoarticular infections. Secondary objectives include evaluating the pharmacokinetics of the partner antibiotic (levofloxacin or ciprofloxacin), investigating the correlation between antibiotic exposure metrics (AUC, Cmax, AUC...

Beta-lactam Monotherapy Versus Beta-lactam Plus Levofloxacin for the Treatment of Streptococcal Bacteremia: A Multicenter, Randomized, Double-Blind, Pragmatic Trial

Enrollment Status: Recruiting

Publish Date: August 21, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: A double-blind randomized controlled trial comparing beta-lactam plus levofloxacin versus beta-lactam monotherapy for the treatment of Streptococcal bacteremia

View All Clinical Trials